125 related articles for article (PubMed ID: 8814378)
21. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.
Holland HK; Dix SP; Geller RB; Devine SM; Heffner LT; Connaghan DG; Hillyer CD; Hughes LL; Miller RL; Moore MR; Winton EF; Wingard JR
J Clin Oncol; 1996 Apr; 14(4):1156-64. PubMed ID: 8648370
[TBL] [Abstract][Full Text] [Related]
22. High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant.
Myers SE; Mick R; Williams SF
Bone Marrow Transplant; 1994 Apr; 13(4):449-54. PubMed ID: 8019470
[TBL] [Abstract][Full Text] [Related]
23. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer.
Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Sniecinski I
Cancer; 1994 Jan; 73(1):125-34. PubMed ID: 7903906
[TBL] [Abstract][Full Text] [Related]
24. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin.
Ayash LJ; Elias A; Schwartz G; Wheeler C; Ibrahim J; Teicher BA; Reich E; Warren D; Lynch C; Richardson P; Schnipper L; Frei E; Antman K
J Clin Oncol; 1996 Nov; 14(11):2984-92. PubMed ID: 8918496
[TBL] [Abstract][Full Text] [Related]
25. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
[TBL] [Abstract][Full Text] [Related]
26. Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support.
van der Lelie H; Baars JW; Rodenhuis S; van Dijk MA; de Glas-Vos CW; Thomas BL; van Oers RH; von dem Borne AE
Cancer; 1995 Dec; 76(11):2338-42. PubMed ID: 8635040
[TBL] [Abstract][Full Text] [Related]
27. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
Bergh J; Wiklund T; Erikstein B; Lidbrink E; Lindman H; Malmström P; Kellokumpu-Lehtinen P; Bengtsson NO; Söderlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Wilking N
Lancet; 2000 Oct; 356(9239):1384-91. PubMed ID: 11052580
[TBL] [Abstract][Full Text] [Related]
28. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer.
Wong R; Rondon G; Saliba RM; Shannon VR; Giralt SA; Champlin RE; Ueno NT
Bone Marrow Transplant; 2003 Jun; 31(12):1157-63. PubMed ID: 12796796
[TBL] [Abstract][Full Text] [Related]
29. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Nagasawa S
Cancer; 1994 Mar; 73(6):1678-85. PubMed ID: 7512436
[TBL] [Abstract][Full Text] [Related]
30. High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer.
Vaughan WP; Reed EC; Edwards B; Kessinger A
Bone Marrow Transplant; 1994 May; 13(5):619-24. PubMed ID: 7914447
[TBL] [Abstract][Full Text] [Related]
31. Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies.
Long GD; Negrin RS; Hoyle CF; Kusnierz-Glaz CR; Schriber JR; Blume KG; Chao NJ
Cancer; 1995 Sep; 76(5):860-8. PubMed ID: 8625190
[TBL] [Abstract][Full Text] [Related]
32. High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast.
Schwartzberg L; Weaver C; Lewkow L; McAneny B; Zhen B; Birch R; West W; Tauer K; Buckner C
Bone Marrow Transplant; 1999 Nov; 24(9):981-7. PubMed ID: 10556957
[TBL] [Abstract][Full Text] [Related]
33. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
[TBL] [Abstract][Full Text] [Related]
34. Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC).
Meisenberg BR; Miller WE; McMillan R
Bone Marrow Transplant; 1996 Dec; 18(6):1087-93. PubMed ID: 8971377
[TBL] [Abstract][Full Text] [Related]
35. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach.
van der Wall E; Nooijen WJ; Baars JW; Holtkamp MJ; Schorangel JH; Richel DJ; Rutgers EJ; Slaper-Cortenbach IC; van der Schoot CE; Rodenhuis S
Br J Cancer; 1995 Apr; 71(4):857-62. PubMed ID: 7536025
[TBL] [Abstract][Full Text] [Related]
36. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.
Ayash LJ; Elias A; Wheeler C; Reich E; Schwartz G; Mazanet R; Tepler I; Warren D; Lynch C; Gonin R
J Clin Oncol; 1994 Jan; 12(1):37-44. PubMed ID: 7505807
[TBL] [Abstract][Full Text] [Related]
37. Acquired episodic complete heart block after high-dose chemotherapy with cyclophosphamide and thiotepa.
Ramireddy K; Kane KM; Adhar GC
Am Heart J; 1994 Mar; 127(3):701-4. PubMed ID: 8122625
[No Abstract] [Full Text] [Related]
38. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer.
Rodenhuis S; Westermann A; Holtkamp MJ; Nooijen WJ; Baars JW; van der Wall E; Slaper-Cortenbach IC; Schornagel JH
J Clin Oncol; 1996 May; 14(5):1473-83. PubMed ID: 8622061
[TBL] [Abstract][Full Text] [Related]
39. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
Cheng YC; Rondón G; Yang Y; Smith TL; Gajewski JL; Donato ML; Shpall EJ; Jones R; Hortobagyi GN; Champlin RE; Ueno NT
Biol Blood Marrow Transplant; 2004 Nov; 10(11):794-804. PubMed ID: 15505610
[TBL] [Abstract][Full Text] [Related]
40. The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis.
van der Wall E; Schaake-Koning CC; van Zandwijk N; Baars JW; Schornagel JH; Richel DJ; Rutgers EJ; Borger JH; Beijnen JH; Rodenhuis S
Eur J Cancer; 1996 Aug; 32A(9):1490-7. PubMed ID: 8911107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
